BB Good human data, but mixed outcomes or surrogate markers. How we grade →Randomized controlled trial (no placebo) · 18,645 Japanese adults
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis
M Yokoyama, H Origasa, M Matsuzaki, Y Matsuzawa, Y Saito, Y Ishikawa et al. Lancet. 2007.
- In plain language
- JELIS: 1.8 g a day of EPA added to a statin lowered major coronary events from 3.5% to 2.8% (19% relative) over 4.6 years; coronary death did not differ.
- Limits
- Open label with no placebo; benefit came from nonfatal events; high-fish-intake Japanese population on low-dose statins.
- Which of our grades it feeds
- CC Small or few human trials. Promising, not proven. How we grade →Science summary: Omega-3: triglycerides, heart outcomes and why the big trials differ
- Source
- doi.org/10.1016/S0140-6736(07)60527-3 · PubMed 17398308
Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.